Evaluation of serum nidogen-2 as a screening and diagnostic tool for ovarian cancer
Gynecologic and Obstetric Investigation Nov 12, 2017
Torky HA, et al. - Nidogen-2 is a new tumour marker that when combined with higher sensitivity, specificity and accuracy than carbohydrate antigen (CA-125) and Doppler ultrasound improves the early diagnosis of ovarian cancer. In this study, Nidogen-2 was shown to be a new promising ovarian malignancy biomarker. It correlated closely with ultrasound and CA125, and also improved the accuracy of diagnosis.
Only Doctors with an M3 India account can read this article. Sign up for free or login with your existing account.
4 reasons why Doctors love M3 India
-
Exclusive Write-ups & Webinars by KOLs
-
Daily Quiz by specialty
-
Paid Market Research Surveys
-
Case discussions, News & Journals' summaries